MetaVia (MTVA) vs Alaunos Therapeutics (TCRT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alaunos Therapeutics is the larger company by market cap ($7.0 million vs $6.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTVA | TCRT |
|---|---|---|
| Share price | $1.01 | $1.66 |
| Market cap | $6.81M | $6.99M |
| 1-day change | -7.34% | +3.75% |
| EPS (TTM) | $-2.78 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.00K |
| Revenue growth (YoY) | — | -50.00% |
| Net income (latest FY) | $-12.97M | $-4.18M |
| Operating margin | — | -84500.00% |
| Net margin | — | -83520.00% |
| 52-week high | $13.42 | $4.50 |
| 52-week low | $0.966 | $0.72 |
| Distance from 52-week high | -92.47% | -63.11% |
| Analyst consensus | none | — |
| Avg. price target upside | +1813.86% | — |
| Average volume | 113.44K | 7.56M |
| Shares outstanding | 6.74M | 4.21M |
| Employees | 8 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Alaunos Therapeutics
TCRT stock →Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
MTVA vs TCRT FAQ
Which is bigger, MetaVia or Alaunos Therapeutics?
Alaunos Therapeutics (TCRT) is larger, with a market capitalization of $6.99M compared with $6.81M for MetaVia (MTVA).
Are MetaVia and Alaunos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.